How Will the Myelodysplastic Syndrome (MDS) Drugs Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the Myelodysplastic Syndrome (MDS) Drugs market grown in recent years?
The market size for drugs addressing myelodysplastic syndrome (MDS) has markedly expanded in the preceding years. It’s projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.5%. Factors such as an ageing population, advancements in targeted therapies, increased awareness, and clinical trials have contributed to its growth during the historical period.
How is the myelodysplastic syndrome (mds) drugs market size expected to evolve during the forecast period?
In the forthcoming years, the market for myelodysplastic syndrome (MDS) drugs is projected to witness robust growth. The market is predicted to attain a value of $5.12 billion by 2029, expanding at a compound annual growth rate (CAGR) of 8.2%. This enhancement during the forecast period can be ascribed to elements such as genomic research, immunotherapies, worldwide healthcare expansion and biomarker identification. Prominent trends expected in this period encompass personalized medicine, combinatorial therapies, symptom management, and data sharing and collaboration.
Get your myelodysplastic syndrome (mds) drugs market report here!
Which key drivers are propelling the myelodysplastic syndrome (mds) drugs market’s growth?
The growth of the myelodysplastic syndrome (MDS) drug market is anticipated to rise due to growing exposure to cancer therapies such as chemotherapy and radiation. Chemotherapy, which involves medications to eliminate cancer cells, and radiation, a treatment that uses high radiation doses to destroy cancer cells and shrink tumors, both have damaging effects on the bone marrow’s stem cells. These cells are responsible for creating new blood cells and their disruption could lead to the development of MDS. MDS drugs, beneficial for managing and treating MDS, a group of disorders that result in abnormal production of blood cells in the bone marrow, are needed. As per an analysis by the European Society of Radiation Oncology (ESTRO), a Belgium-based organization, it is projected that by 2025, there will be a 16% increase in radiotherapy treatment courses. Therefore, the myelodysplastic syndrome (MDS) drug market growth is being prompted by increasing exposure to cancer treatments like chemotherapy and radiation. In addition, the surge in cases of myeloid leukemia is expected to further stimulate the expansion of the myelodysplastic syndrome (MDS) drug treatment market. Myeloid leukemia, a cancer originating from the bone marrow affecting the cells that produce various blood cells, can be targeted directly by MDS drugs. These drugs work to improve bone marrow function, reduce the risk of complications from low blood cell counts, decrease reliance on chemotherapy and transplants, and increase survival rates for individuals with MDS. As indicated by the American Cancer Society, a US-based health organization, the number of acute myeloid leukemia (AML) cases is predicted to be approximately 20,380 with 11,310 fatalities in adults during 2023. Therefore, the rise in myeloid leukemia cases is a key growth driver for the myelodysplastic syndrome (MDS) drug market.
What are the market segments in the myelodysplastic syndrome (mds) drugs industry?
The myelodysplastic syndrome (MDS) drugs market covered in this report is segmented –
1) By Drug Type: Chemotherapy, Immunomodulatory Drugs
2) By Route Of Administration: Oral, Parenteral
3) By Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Chemotherapy: Hypomethylating Agents, Cytotoxic Agents
2) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13043&type=smp
Which leading companies are shaping the growth of the myelodysplastic syndrome (mds) drugs market?
Major companies operating in the myelodysplastic syndrome (mds) drugs market are Bristol Myers Squibb, Otsuka Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Mylan NV, Cipla Limited, Acceleron Pharma Inc., Aprea Therapeutics, Onconova Therapeutics Inc., Geron Corporation, Amgen Inc., Sandoz, Gilead Sciences Inc., Johnson And Johnson, Lupin Ltd. Corporation, Ono Pharmaceutical Co. Ltd., Eisai Co. Ltd., Nippon Shinyaku Co. Ltd., Lupin Ltd., Accord Healthcare Inc., Kite Pharma Inc., Karyopharm Therapeutics Inc., Aprea Therapeutics Inc., Acceleron Pharma Inc., Astex Pharmaceuticals Inc., Stemline Therapeutics Inc., Geron Corporation, Onconova Therapeutics Inc., Actinium Pharmaceuticals Inc., Millennium Pharmaceuticals Inc.
What key trends are currently impacting the myelodysplastic syndrome (mds) drugs market’s development?
Major firms in the myelodysplastic syndrome (MDS) drug market dedicate their efforts to the creation of novel products such as targeted therapies with the intention to boost patient health results, fulfill distinct customer requirements, and adapt to the environment. Targeted treatments for myelodysplastic syndromes (MDS) deploy specific drugs that identify and target genetic alterations or molecular irregularities in cancer cells with the purpose of enhancing results by selectively focusing on abnormal cells, aiming to reduce harm to normal tissues. For example, in October 2023, Tibsovo (ivosidenib) was authorized by the U.S. Food and Drug Administration (FDA) for the treatment of adults suffering from relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation. The effectiveness of using Tibsovo for this fresh use was assessed in a single-arm, open-label, multicenter study of 18 adult patients with relapsed or refractory MDS with an IDH1 mutation.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
Which geographic areas are influencing the growth of the myelodysplastic syndrome (mds) drugs market?
North America was the largest region in the myelodysplastic syndrome (MDS) drugs market in 2024. The regions covered in myelodysplastic syndrome (MDS) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Similar Reports By The Business Research Company:
Dermatology Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report
Respiratory Diseases Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/respiratory-disease-drugs-global-market-report
Gastrointestinal Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
